These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 31767751)
1. High-throughput assessment of hemoglobin polymer in single red blood cells from sickle cell patients under controlled oxygen tension. Di Caprio G; Schonbrun E; Gonçalves BP; Valdez JM; Wood DK; Higgins JM Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25236-25242. PubMed ID: 31767751 [TBL] [Abstract][Full Text] [Related]
2. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. Schroeder P; Fulzele K; Forsyth S; Ribadeneira MD; Guichard S; Wilker E; Marshall CG; Drake A; Fessler R; Konstantinidis DG; Seu KG; Kalfa TA J Pharmacol Exp Ther; 2022 Mar; 380(3):210-219. PubMed ID: 35031585 [TBL] [Abstract][Full Text] [Related]
3. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells. Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905 [TBL] [Abstract][Full Text] [Related]
4. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. Nakagawa A; Lui FE; Wassaf D; Yefidoff-Freedman R; Casalena D; Palmer MA; Meadows J; Mozzarelli A; Ronda L; Abdulmalik O; Bloch KD; Safo MK; Zapol WM ACS Chem Biol; 2014 Oct; 9(10):2318-25. PubMed ID: 25061917 [TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin. Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781 [TBL] [Abstract][Full Text] [Related]
6. Intracellular polymerization of sickle hemoglobin: disease severity and therapeutic goals. Noguchi CT; Rodgers GP; Schechter AN Prog Clin Biol Res; 1987; 240():381-91. PubMed ID: 3615501 [TBL] [Abstract][Full Text] [Related]
8. Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice. Dufu K; Williams AT; Muller CR; Walser CM; Lucas A; Eaker AM; Alt C; Cathers BE; Oksenberg D; Cabrales P Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H400-H411. PubMed ID: 34213392 [TBL] [Abstract][Full Text] [Related]
9. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309 [TBL] [Abstract][Full Text] [Related]
10. Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease. Henry ER; Cellmer T; Dunkelberger EB; Metaferia B; Hofrichter J; Li Q; Ostrowski D; Ghirlando R; Louis JM; Moutereau S; Galactéros F; Thein SL; Bartolucci P; Eaton WA Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15018-15027. PubMed ID: 32527859 [TBL] [Abstract][Full Text] [Related]
11. Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease. Vunnam N; Hansen S; Williams DC; Been MO; Lo CH; Pandey AK; Paulson CN; Rohde JA; Thomas DD; Sachs JN; Wood DK Biomacromolecules; 2022 Sep; 23(9):3822-3830. PubMed ID: 35944154 [TBL] [Abstract][Full Text] [Related]
12. Polymerization in erythrocytes containing S and non-S hemoglobins. Noguchi CT Biophys J; 1984 Jun; 45(6):1153-8. PubMed ID: 6743746 [TBL] [Abstract][Full Text] [Related]
13. Effect of hemoglobin concentration on nucleation and polymer formation in sickle red blood cells. Corbett JD; Mickols WE; Maestre MF J Biol Chem; 1995 Feb; 270(6):2708-15. PubMed ID: 7852341 [TBL] [Abstract][Full Text] [Related]
14. Polymerization of hemoglobin in sickle trait erythrocytes and lysates. Noguchi CT; Torchia DA; Schechter AN J Biol Chem; 1981 May; 256(9):4168-71. PubMed ID: 7217076 [TBL] [Abstract][Full Text] [Related]
15. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Oder E; Safo MK; Abdulmalik O; Kato GJ Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087 [TBL] [Abstract][Full Text] [Related]
16. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia. Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381 [TBL] [Abstract][Full Text] [Related]
17. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease. Demers M; Sturtevant S; Guertin KR; Gupta D; Desai K; Vieira BF; Li W; Hicks A; Ismail A; Gonçalves BP; Di Caprio G; Schonbrun E; Hansen S; Musayev FN; Safo MK; Wood DK; Higgins JM; Light DR Blood Adv; 2021 Mar; 5(5):1388-1402. PubMed ID: 33661300 [TBL] [Abstract][Full Text] [Related]
18. Hybrid erythrocytes for membrane studies in sickle cell disease. Clark MR; Shohet SB Blood; 1976 Jan; 47(1):121-31. PubMed ID: 1244907 [TBL] [Abstract][Full Text] [Related]